| Publications | PubMed=2469723; DOI=10.4049/jimmunol.142.10.3692
Anichini A., Mazzocchi A., Fossati G., Parmiani G.
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
J. Immunol. 142:3692-3701(1989) PubMed=2776368; DOI=10.1007/BF01753674
Larizza L., Doneda L., Rodolfo M., Fossati G.
High incidence of chromosomal lesions involving C-heterochromatin in four human melanoma lines.
Clin. Exp. Metastasis 7:633-644(1989) PubMed=8459226; DOI=10.1084/jem.177.4.989; PMCID=PMC2190978
Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., Herlyn M., Parmiani G.
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
J. Exp. Med. 177:989-998(1993) PubMed=7520026; DOI=10.1002/ijc.2910580413
Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.
Expression of the co-stimulatory molecule B7 on melanoma cells.
Int. J. Cancer 58:527-532(1994) PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#
Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.
Expression of the co-stimulatory molecule CD40 on melanoma cells.
Int. J. Cancer 68:795-801(1996) PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195
Thomas W.D., Hersey P.
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
J. Immunol. 161:2195-2200(1998) DOI=10.1007/0-306-46872-7_16
Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.
Melanoma: the Milan melanoma cell lines.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999) PubMed=9973437; DOI=10.4049/jimmunol.162.3.1739
Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L., Ravagnani F., Gallino F., Belli F., Parmiani G.
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
J. Immunol. 162:1739-1748(1999) PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012) PubMed=25576923; DOI=10.18632/oncotarget.2995; PMCID=PMC4413617
Loria R., Bon G., Perotti V., Gallo E., Bersani I., Baldassari P., Porru M., Leonetti C., Di Carlo S., Visca P., Brizzi M.F., Anichini A., Mortarini R., Falcioni R.
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
Oncotarget 6:2779-2793(2015) |
|---|
